Associated to the humanized mAb lintuzumab, the corresponding targeted 227Th conjugate (227Th-lintuzumab or CD33-TTC) was studied for the targeting of CD33, a sialic acid transmembrane receptor expressed in blood cancers and especially acute myeloid leukemia. The gene discussed is CD33; the disease is hematopoietic and lymphoid system neoplasm.